Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• The studies primarily focused on antiretroviral therapy (ART)-naive people with HIV (PWH) and virologically suppressed PWH, demonstrating that dolutegravir/lamivudine maintained high rates of virologic suppression (97-100% at Week 48) with low rates of virologic failure (0-3.3 per 100 person-years), comparable to other regimens such as bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/abacavir /lamivudine (DTG/ABC/3TC) at Week 144.
• Inflammatory biomarker assessments indicated significant changes favoring dolutegravir/lamivudine, particularly in studies like TANGO and SALSA, where soluble CD14 levels were positively impacted, highlighting the potential additional benefits of this regimen in managing inflammatory processes in virologically suppressed PWH.
• Studies included diverse age groups, primarily those aged ≥18 years, and real-world evidence showed that dolutegravir/lamivudine was effective across various populations, supporting its use in broader clinical settings.
• Serious Adverse Events: Dolutegravir/lamivudine was associated with fewer serious adverse events compared to BIC/FTC/TAF (odds ratio (OR) 0.51; 95% confidence interval (CI) 0.29-0.87; P = 0.014) and DTG/ABC/3TC (OR 0.38; 95% CI 0.19-0.75; P = 0.006) in the evaluated populations, which included both ART-naive and virologically suppressed PWH.
• Adverse Drug Reactions and Discontinuations: There were no significant differences in adverse drug reactions leading to treatment discontinuation between dolutegravir/lamivudine and triple-drug regimens (relative risk (RR) 1.74; 95% CI 0.73-4.17; P = 0.215), and real-world studies indicated low rates of discontinuation due to adverse events, consistent with trial data, with discontinuations reported in 13.6% (95% CI: 11.1-16.2) of patients at Week 48.
• Population Types and Subgroup Considerations: The studies included specific populations such as ART-PWH and virologically suppressed PWH, with dolutegravir/lamivudine compared with other regimens in ART-naive PWH. High rates of virologic suppression (97-100% at Week 48) and low rates of virologic failure (0-3.3 per 100 person-years) for dolutegravir/lamivudine were reported, indicating its effectiveness across these groups.